C-suites are being forced to include tariff dynamics into their short-term and long-term strategies.
Combining human expertise with AI creates safer, faster, and more innovative medtech solutions.
For the industry’s CDMOs, the future winners will not be defined by capacity or cost alone, but by their ability to co-engineer procedures.
In the first edition of 2026 of Today’s Medical Developments Magazine, MedWorld Advisors discusses how mergers and acquisitions will continue to play a strong role in shaping the next generation of MedTech industry innovation.
Passivity will not be rewarded in 2026—strategic acquirers have returned to the market in force.
Attendees gained a clear understanding of how global tariffs are reshaping both organic growth strategies and inorganic activities like M&A within the MedTech industry.
Join us Wednesday May 13, 2026 at 12PM ET as MedWorld Advisors explores the value impacts of AI in MedTech in 2026 for MedTech companies at all stages of growth – from start-up to scale-up including operational excellence through M&A Exit.
The lasting impression from AAOS 2026 is that the orthopedic industry is not waiting for the future.